Diving shorts:

• According to the report of market data research company Pitchbook, 2025 Increased venture capital investment in 2025.
• In the first quarter, the VC funding amounted to $ 4.1 billion is the highest from 2022.
• However, the increase in Medtech merger and acquisitions Pitchbook has not yet appeared under the Second Trump administration, and antitrust regulatory authorities are still challenging.

Diving insight:

According to Pitchbook, Medtech VC, both 2022 and 2023 decreased. Last year, there were signs that the market could be the lowest. The number of VC investment decreased for the third consecutive year, but the amount of funding was greater than 2023.

Signs of recovery of the VC continued until 2025. In the first quarter when $ 260 million USD Investment During the entire body competition, the Neko Health was the largest of the 11 rounds worth $ 100 million or more. With Elon Musk’s brain implanting ‘neurralink’ to raise $ 650 million This month, Pitchbook said preliminary second quarter data shows more than $ 3 billion to Medtech VC funding so far.

Still, venture capital exits are rare. Pitchbook said there were no significant Medtech VC outputs in the first quarter, and the total exit value remained around the previous two quarters. The entire output value in recent years has been due to the rare large transactions, such as the „Tempus AI” initial public offer in 2024. And ATHELAS $ 6 billion in 2023

Pitchbook emphasized three noticeable exits that are closed in the first quarter: Beta Bionics IPOHologics’ The takeover of $ 350 million from the Gynsonics and Boston Scientific 540 million Acquisition of USD From Sonivie. The level of activity is not in the expectations of Pitchbook.

„The earlier thesis that the new US presidential administration’s gentler regulatory position will encourage merger and acquisition activities has not yet been overwhelmed because the wider market restlessness has difficult transactions in all sectors in early 2025,” said Pitchbook. „In addition, regulatory resistance remains wind wind.”

Pitchbook has indicated the legal challenge of the Federal Trade Commission $ 627 million. USD to redeem private capital from Surmodics as evidence of constant regulatory resistance. FPK challenged the agreement Based on this, „it would cause a highly concentrated market for hydrophic coatings and remove significant competition from head to head.”